Valuation: Gilead Sciences, Inc.

Market Cap 162B 143B 133B 122B 229B 15,687B 233B 1,578B 616B 7,690B 610B 597B 26,611B P/E 2026 *
-47.1x
P/E 2027 * 16.6x
Enterprise Value 172B 151B 141B 129B 242B 16,600B 246B 1,670B 652B 8,137B 645B 631B 28,161B EV / Sales 2026 *
5.65x
EV / Sales 2027 * 5.03x
Free-Float
99.88%
Yield 2026 *
2.52%
Yield 2027 * 2.61%
1 day-0.05%
1 week-5.13%
Current month+2.35%
1 month+3.41%
3 months-3.24%
6 months-4.87%
Current year+5.35%
1 week 127.61
Extreme 127.61
135.5
1 month 123.67
Extreme 123.67
140.61
Current year 116.88
Extreme 116.88
157.29
1 year 108.46
Extreme 108.4601
157.29
3 years 62.07
Extreme 62.07
157.29
5 years 57.16
Extreme 57.165
157.29
10 years 56.56
Extreme 56.56
157.29
Manager TitleAgeSince
Chief Executive Officer 61 2019-02-28
Director of Finance/CFO 56 2019-10-31
Compliance Officer - 2025-12-17
Director TitleAgeSince
Director/Board Member 58 2016-08-18
Director/Board Member 73 2017-12-31
Director/Board Member 72 2018-05-08
Date Insider Type Main position Quantity % Market Cap.
7/15/26 Sell

Executive/Senior Manager

-3,000 0.0002%
7/15/26 Sell

Chief Financial Officer

-3,000 0.0002%
7/1/26 Sell

Chief Executive Officer

-15,000 0.0012%
Change 5-day change 1-year change 3-year change Capi.($)
-1.18%-5.13%+13.87%+60.35% 162B
+0.86%+2.30%+49.71%+158.86% 1,057B
+1.59%+5.37%+55.77%+54.77% 624B
+0.95%+1.95%+36.11%+80.44% 454B
+1.60%+7.09%+35.90%+29.32% 341B
-0.60%+2.95%+36.28%+39.04% 297B
-0.14%+0.33%+18.70%+17.64% 262B
+0.09%-4.53%-27.60%-42.19% 215B
+1.22%+1.20%+21.61%+60.14% 201B
-0.16%-2.39%-3.23%-34.39% 143B
Average +0.18%+0.64%+23.71%+42.40% 375.65B
Weighted average by Cap. +0.13%+1.49%+35.10%+72.61%

Financials

2026 *2027 *
Net sales 30.42B 26.77B 24.88B 22.84B 42.87B 2,937B 43.59B 295B 115B 1,440B 114B 112B 4,983B 32.28B 28.41B 26.4B 24.24B 45.49B 3,117B 46.26B 314B 122B 1,528B 121B 119B 5,288B
Net income -3.39B -2.98B -2.77B -2.55B -4.78B -327B -4.86B -32.93B -12.86B -160B -12.73B -12.45B -555B 9.76B 8.59B 7.98B 7.33B 13.76B 943B 13.99B 94.8B 37.02B 462B 36.64B 35.85B 1,599B
Net Debt 9.46B 8.32B 7.74B 7.1B 13.33B 913B 13.56B 91.87B 35.88B 448B 35.51B 34.75B 1,549B -
Logo Gilead Sciences, Inc.
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.2%): for the treatment of HIV (71.8% of net sales), oncology diseases (11.2%), hepatitis B virus (11.1%), Ebola virus (3.2%) and other (2.7%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.8%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (70.9%), Europe (17.2%) and other (11.9%).
Employees
17,000
Date Price Change Volume
26-07-24 $129.31 -1.18% 5,418,526
26-07-23 $130.86 +0.40% 6,299,287
26-07-22 $130.34 +0.05% 4,757,764
26-07-21 $130.28 -2.20% 8,371,109
26-07-20 $133.21 -0.80% 4,103,979
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
130.86USD
Average target price
157.56USD
Spread / Average Target
+20.40%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GILD Stock